Table 1.
Clinical Studies of Active Surveillance in Patients with Low-Risk Papillary Thyroid Microcarcinoma
| First Author, Country, Year | No. of patients | Duration of follow-up (months) | Tumor size enlargement (≥3 mm) | Tumor volume increase (>50%) | Development of lymph node metastasis |
|---|---|---|---|---|---|
| Ito, Japan, 2014 (8) | 1235 | Mean, 60 | 4.6% in total | ND | 1.5% in total |
| 4.9%/5 years | 1.7%/5 years | ||||
| 8.0%/10 years | 3.8%/10 years | ||||
| Fukuoka, Japan, 2016 (15) | 409 | Mean, 81.6 | 6.0% in total | ND | 1.0% in total |
| 6.3%/5 years | |||||
| 7.3%/10 years | |||||
| Tuttle, USA, 2017 (16) | 291a | Median, 25 | 3.8% in total | 12.4% | 0% |
| 2.5%/2 years | 11.5%/2 years | ||||
| 12.1%/10 years | 24.8%/5 years | ||||
| Oh, Korea, 2018 (17) | 370 | Median, 32.5 | 3.5% | 23.2% | 1.4% |
| Sanabria, Colombia, 2018 (18) | 57a | Median, 13.3 | 3.5% | ND | ND |
| Molinaro, Italy, 2020 (19) | 93 | Median, 19 | 2.1% | 16% | 1.1% |
a
Included patients with papillary thyroid carcinoma 10–15 mm in diameter.
ND, no data.